Annual FCF
-$23.76 M
+$8.32 M+25.93%
31 December 2023
Summary:
Enlivex Therapeutics annual free cash flow is currently -$23.76 million, with the most recent change of +$8.32 million (+25.93%) on 31 December 2023. During the last 3 years, it has fallen by -$11.73 million (-97.56%). ENLV annual FCF is now -15845.64% below its all-time high of -$149.00 thousand, reached on 31 December 2012.ENLV Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$1.81 M
+$2.74 M+60.18%
30 June 2024
Summary:
Enlivex Therapeutics quarterly free cash flow is currently -$1.81 million, with the most recent change of +$2.74 million (+60.18%) on 30 June 2024. Over the past year, it has increased by +$3.65 million (+66.84%). ENLV quarterly FCF is now -154.25% below its all-time high of $3.34 million, reached on 31 December 2017.ENLV Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$17.12 M
+$5.25 M+23.46%
30 June 2024
Summary:
Enlivex Therapeutics TTM free cash flow is currently -$17.12 million, with the most recent change of +$5.25 million (+23.46%) on 30 June 2024. Over the past year, it has increased by +$8.76 million (+33.84%). ENLV TTM FCF is now -1725.64% below its all-time high of $1.05 million, reached on 30 September 2018.ENLV TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ENLV Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +25.9% | +66.8% | +33.8% |
| 3 y3 years | -97.6% | +58.0% | +3.7% |
| 5 y5 years | -556.0% | +12.5% | -148.8% |
ENLV Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -97.6% | +25.9% | at high | +85.7% | at high | +49.4% |
| 5 y | 5 years | -556.0% | +25.9% | -345.0% | +85.7% | -220.1% | +49.4% |
| alltime | all time | <-9999.0% | +25.9% | -154.3% | +85.7% | -1725.6% | +49.4% |
Enlivex Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | -$1.81 M(-60.2%) | -$17.12 M(-23.5%) |
| Mar 2024 | - | -$4.55 M(-13.8%) | -$22.37 M(-5.9%) |
| Dec 2023 | -$23.76 M(-25.9%) | -$5.28 M(-3.4%) | -$23.76 M(-8.2%) |
| Sept 2023 | - | -$5.47 M(-22.6%) | -$25.87 M(-8.2%) |
| June 2023 | - | -$7.06 M(+18.8%) | -$28.19 M(-16.6%) |
| Mar 2023 | - | -$5.95 M(-19.6%) | -$33.80 M(+5.4%) |
| Dec 2022 | -$32.08 M(+67.3%) | -$7.40 M(-4.9%) | -$32.08 M(-0.7%) |
| Sept 2022 | - | -$7.78 M(-38.6%) | -$32.30 M(+12.0%) |
| June 2022 | - | -$12.67 M(+200.2%) | -$28.84 M(+38.1%) |
| Mar 2022 | - | -$4.22 M(-44.6%) | -$20.88 M(+8.9%) |
| Dec 2021 | -$19.17 M(+59.4%) | -$7.62 M(+76.4%) | -$19.17 M(+7.8%) |
| Sept 2021 | - | -$4.32 M(-8.2%) | -$17.78 M(+9.9%) |
| June 2021 | - | -$4.71 M(+87.4%) | -$16.19 M(+5.9%) |
| Mar 2021 | - | -$2.51 M(-59.7%) | -$15.28 M(+27.0%) |
| Dec 2020 | -$12.03 M(+66.2%) | -$6.24 M(+129.0%) | -$12.03 M(+60.9%) |
| Sept 2020 | - | -$2.73 M(-28.3%) | -$7.47 M(+9.6%) |
| June 2020 | - | -$3.80 M(-613.6%) | -$6.82 M(+27.5%) |
| Mar 2020 | - | $740.00 K(-143.9%) | -$5.35 M(-26.1%) |
| Dec 2019 | -$7.23 M(+99.7%) | -$1.69 M(-18.6%) | -$7.23 M(+5.1%) |
| Sept 2019 | - | -$2.07 M(-11.0%) | -$6.88 M(+24.7%) |
| June 2019 | - | -$2.33 M(+103.1%) | -$5.52 M(+46.7%) |
| Mar 2019 | - | -$1.15 M(-14.0%) | -$3.76 M(+3.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$3.62 M(+48.8%) | -$1.33 M(+87.5%) | -$3.62 M(-444.0%) |
| Sept 2018 | - | -$711.00 K(+24.1%) | $1.05 M(+51.3%) |
| June 2018 | - | -$573.00 K(-43.0%) | $696.00 K(-204.2%) |
| Mar 2018 | - | -$1.00 M(-130.1%) | -$668.00 K(-72.6%) |
| Dec 2017 | -$2.43 M(-84.3%) | $3.34 M(-412.9%) | -$2.43 M(-72.2%) |
| Sept 2017 | - | -$1.07 M(-44.9%) | -$8.76 M(-17.0%) |
| June 2017 | - | -$1.94 M(-30.1%) | -$10.55 M(-26.3%) |
| Mar 2017 | - | -$2.77 M(-7.0%) | -$14.32 M(-7.6%) |
| Dec 2016 | -$15.50 M(+16.6%) | -$2.98 M(+4.1%) | -$15.50 M(-4.2%) |
| Sept 2016 | - | -$2.86 M(-49.8%) | -$16.18 M(-1.9%) |
| June 2016 | - | -$5.71 M(+44.2%) | -$16.50 M(+20.6%) |
| Mar 2016 | - | -$3.96 M(+8.1%) | -$13.68 M(+2.9%) |
| Dec 2015 | -$13.30 M(+197.3%) | -$3.66 M(+15.3%) | -$13.30 M(+19.7%) |
| Sept 2015 | - | -$3.17 M(+9.9%) | -$11.11 M(+15.4%) |
| June 2015 | - | -$2.89 M(-19.1%) | -$9.63 M(+29.5%) |
| Mar 2015 | - | -$3.57 M(+142.2%) | -$7.43 M(+66.3%) |
| Dec 2014 | -$4.47 M(+415.8%) | -$1.48 M(-13.0%) | -$4.47 M(+49.2%) |
| Sept 2014 | - | -$1.70 M(+145.1%) | -$3.00 M(+130.4%) |
| June 2014 | - | -$692.00 K(+13.6%) | -$1.30 M(+113.6%) |
| Mar 2014 | - | -$609.00 K | -$609.00 K |
| Dec 2013 | -$867.00 K(+481.9%) | - | - |
| Dec 2012 | -$149.00 K | - | - |
FAQ
- What is Enlivex Therapeutics annual free cash flow?
- What is the all time high annual FCF for Enlivex Therapeutics?
- What is Enlivex Therapeutics annual FCF year-on-year change?
- What is Enlivex Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Enlivex Therapeutics?
- What is Enlivex Therapeutics quarterly FCF year-on-year change?
- What is Enlivex Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Enlivex Therapeutics?
- What is Enlivex Therapeutics TTM FCF year-on-year change?
What is Enlivex Therapeutics annual free cash flow?
The current annual FCF of ENLV is -$23.76 M
What is the all time high annual FCF for Enlivex Therapeutics?
Enlivex Therapeutics all-time high annual free cash flow is -$149.00 K
What is Enlivex Therapeutics annual FCF year-on-year change?
Over the past year, ENLV annual free cash flow has changed by +$8.32 M (+25.93%)
What is Enlivex Therapeutics quarterly free cash flow?
The current quarterly FCF of ENLV is -$1.81 M
What is the all time high quarterly FCF for Enlivex Therapeutics?
Enlivex Therapeutics all-time high quarterly free cash flow is $3.34 M
What is Enlivex Therapeutics quarterly FCF year-on-year change?
Over the past year, ENLV quarterly free cash flow has changed by +$3.65 M (+66.84%)
What is Enlivex Therapeutics TTM free cash flow?
The current TTM FCF of ENLV is -$17.12 M
What is the all time high TTM FCF for Enlivex Therapeutics?
Enlivex Therapeutics all-time high TTM free cash flow is $1.05 M
What is Enlivex Therapeutics TTM FCF year-on-year change?
Over the past year, ENLV TTM free cash flow has changed by +$8.76 M (+33.84%)